Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
08:00am, Wednesday, 17'th Sep 2025
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place fr
TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 202
Teva Pharmaceutical Industries Limited (TEVA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
12:57pm, Tuesday, 09'th Sep 2025
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Richard Francis - President, CEO & Direct
Colorado must face Teva's lawsuit over free allergy pen law
03:57pm, Friday, 05'th Sep 2025
Colorado must face Teva Pharmaceutical Industries' lawsuit challenging a state law requiring it to provide free generic EpiPens to pharmacies, a federal appeals court said Friday.
TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?
11:31am, Thursday, 04'th Sep 2025
Teva expects 2025 generics growth to be flat to low single digit, with U.S. trends and the Japan divestment influencing results.
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
04:30pm, Tuesday, 02'nd Sep 2025
TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcom
US FDA approves Teva Pharmaceuticals' generic obesity drug
09:17am, Thursday, 28'th Aug 2025
The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' cheaper generic version of Novo Nordisk's older weight-loss drug, Saxenda, the Israel-based company said on Thursday.
Teva's Pivot To (Innovative) Growth: Re-Rating Should Continue
01:43am, Thursday, 28'th Aug 2025
Teva offers strong value upside through disciplined execution and does not require growth surprise. Innovative drugs like Austedo have generated consistent revenue growth in the past three years, and
Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive Quarters
03:51am, Wednesday, 20'th Aug 2025
Data is the fuel that powers Wall Street. Unfortunately, the amount of data investors have to digest can sometimes be overwhelming.
Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”
09:00am, Tuesday, 19'th Aug 2025
GOLETA, Calif.--(BUSINESS WIRE)--Teva unveils AW25 footwear collection.
US FDA approves Teva's Ajovy for migraine prevention in children
06:16pm, Tuesday, 05'th Aug 2025
The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva Pharma , to help prevent migraines in children aged six and older who weigh 45 kilograms or
Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside
03:27pm, Thursday, 31'st Jul 2025
Teva is transforming, with management delivering on profit growth, specialty drug expansion, and improving its balance sheet—yet the stock remains undervalued. Specialty products like AUSTEDO and UZ
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
01:41pm, Thursday, 31'st Jul 2025
TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.
Teva CEO: Our supply chain puts us in a strong position
12:40pm, Wednesday, 30'th Jul 2025
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.
Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript
11:50am, Wednesday, 30'th Jul 2025
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Christopher J. Stevo - Senior Vice President of Investor Relations &
